To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves cUTI combo from MDCO

After market close Tuesday, FDA said it approved Vabomere meropenem/vaborbactam from The Medicines Co. (NASDAQ:MDCO) to treat adults

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE